Literature DB >> 8824931

Interactions of FK506 (tacrolimus) with clinically important drugs.

H Matsuda1, K Iwasaki, T Shiraga, Z Tozuka, T Hata, F P Guengerich.   

Abstract

The effect of eight drugs on the metabolism of FK506 (tacrolimus) by human liver microsomes was studied at a substrate concentration of 10 microM. NADPH-dependent oxidative metabolism of FK506 was inhibited 20, 15, and 10% by quinidine, omeprazole, and sulindac, respectively, at 100 microM. Theophylline, diclofenac, indomethacin, phenylbutazone, and cimetidine (at ten times molar excess of FK506) and all eight drugs (at equal molar concentration) had slight effects on metabolism. The effects of these drugs were much weaker than that of cyclosporin A. The effect of FK506 on NADPH-dependent oxidation of prednisolone and theophylline by human liver microsomes were also studied. FK506 inhibited prednisolone metabolism in a concentration-dependent manner but exhibited a negligible effect on theophylline metabolism. The results suggest potential for interactions between FK506 and drugs metabolized by the cytochrome P450 3A subfamily.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824931

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  7 in total

Review 1.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 2.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Clinically significant drug interactions with new immunosuppressive agents.

Authors:  C Mignat
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

4.  Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Authors:  Gwenn E McLaughlin; Michelle Schober; Maria Perez; Phillip Ruiz; Bernard W Steele; Carolyn Abitbol
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 5.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 7.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.